Spackman Equities Group Inc. Engaged to Advise CanariaBio Inc. on TSX Venture Exchange
The common shares of Spackman Equities Group trades on the TSX Venture Exchange under the symbol SQG. Visit www.spackmanequities.com for further information.
Cure Today15d
Understanding the FDA Approval of Enhertu in HER2-Low and -Ultralow Breast Cancer
Enhertu is approved for HR-positive, HER2-low or -ultralow metastatic breast cancer, expanding treatment options for these patients. DESTINY-Breast06 trial showed Enhertu reduced disease progression ...
Oncology Nurse Advisor16d
Nivolumab Added to Chemo Improves Response in ER+, HER2− Breast Cancer
Adding nivolumab to neoadjuvant chemotherapy significantly increases pathological complete response rates. (HealthDay News) — For patients with high-risk, early-stage estrogen receptor (ER ...
Cure Today17d
Understanding the Distinction Between HER2-Low and HER2-Ultralow Breast Cancer
Dr. Debu Tripathy discussed the importance of understanding the distinctions between HER2-low and HER2-ultralow breast cancer. All patients with breast cancer who may be candidates for antibody-drug ...
Oncology Nurse Advisor20d
Enhertu Approved for HR+, HER2-Low/Ultralow Metastatic Breast Cancer
In the HER2-low population, treatment with trastuzumab deruxtecan reduced the risk of disease progression or death by 38% compared with chemotherapy. The Food and Drug Administration (FDA ...
National Institute for Health and Care Excellence22d
Olaparib for treating BRCA mutation-positive HER2-negative advanced breast cancer after chemotherapy
There is a commercial access agreement for olaparib. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact ...
Targeted Oncology29d
FDA Expands PATHWAY HER2 (4B5) Test to Include HER2-Ultralow Status
The FDA has expanded the label for the PATHWAY anti-HER2/neu (4B5) Rabbit Monoclonal Primary Antibody. This enables the identification of patients with hormone receptor (HR)-positive, HER2-ultralow ...
National Institute for Health and Care Excellence29d
Elacestrant for treating oestrogen receptor-positive HER2-negative advanced breast cancer with an ESR1 mutation after endocrine treatment
There is a simple discount patient access scheme for elacestrant. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact ...
Frontiers29d
A novel nanobody-based HER2-targeting antibody exhibits potent synergistic antitumor efficacy in trastuzumab-resistant cancer cells
Human epithelial growth factor receptor-2 (HER2) plays an oncogenic role in numerous tumors, including breast, gastric, and various other solid tumors. While anti-HER2 therapies are approved for the ...
FierceBiotech1mon
Roche's Enhertu companion diagnostic secures new FDA approval in HER2-ultralow breast cancer
The PATHWAY anti-HER2/neu (4B5) Rabbit Monoclonal Primary Antibody test is used with Roche’s fully automated BenchMark IHC/ISH slide-staining instrument.
New York Post1mon
I was diagnosed with stage 4 cervical cancer at 21 — the symptoms that made me get checked
Two symptoms prompted Jenna Anne Johnson, 21, to undergo a routine pap smear last summer. That test revealed she had Stage 3 cervical cancer that later progressed to Stage 4. Instagram / Jenna ...